Imagion Biosystems Ltd (ASX: IBX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imagion Biosystems Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.21 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 50.44 million
Earnings per share -0.184
Dividend per share N/A
Year To Date Return -89.30%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imagion Biosystems Ltd (ASX: IBX)
    Latest News

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why

    What a turnaround! Imagion shares are skyrocketing after hitting a 52-week low yesterday.

    Read more »

    young female doctor with digital tablet looking confused.
    Share Gainers

    The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What's happening?

    The biotech company has responded to a query from the ASX. Here are the details

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update

    Here's what is driving the Imagion share price higher today.

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Share Gainers

    Imagion (ASX:IBX) share price zips 38% higher. Here's why

    The Imagion Biosystems Ltd share price is up 38% today following an update on its MagSense HER2 breast cancer study.…

    Read more »

    ASX bank profit upgrade Red rocket and arrow boosting up a share price chart
    Healthcare Shares

    Imagion (ASX:IBX) share price up 1,166% in a year pursuing 'radiation-free' cancer tech

    The Imagion Biosystems Ltd share price has rocketed 1,166% over the past 12 months due to a series of promising…

    Read more »

    IBX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imagion Biosystems Ltd

    Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

    IBX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Dec 2024 $0.02 $-0.01 -27.78% 10,128,484 $0.04 $0.04 $0.02
    12 Dec 2024 $0.04 $0.00 0.00% 292,385 $0.04 $0.04 $0.04
    11 Dec 2024 $0.04 $0.00 0.00% 41,951 $0.04 $0.04 $0.04
    10 Dec 2024 $0.04 $0.00 0.00% 765,130 $0.04 $0.04 $0.03
    09 Dec 2024 $0.04 $0.00 0.00% 115,221 $0.04 $0.04 $0.04
    06 Dec 2024 $0.05 $0.00 0.00% 219,113 $0.05 $0.05 $0.04
    05 Dec 2024 $0.05 $0.00 0.00% 418,468 $0.05 $0.05 $0.05
    04 Dec 2024 $0.05 $0.01 23.81% 402,398 $0.04 $0.05 $0.04
    03 Dec 2024 $0.04 $0.00 0.00% 205,923 $0.04 $0.04 $0.04
    02 Dec 2024 $0.04 $0.00 0.00% 39,305 $0.04 $0.04 $0.04
    29 Nov 2024 $0.04 $0.00 0.00% 399,822 $0.04 $0.04 $0.04
    28 Nov 2024 $0.04 $0.01 31.25% 54,413 $0.03 $0.04 $0.03
    27 Nov 2024 $0.03 $0.00 0.00% 269,100 $0.03 $0.03 $0.03
    26 Nov 2024 $0.03 $0.00 0.00% 139,024 $0.04 $0.04 $0.03
    25 Nov 2024 $0.04 $0.00 0.00% 15,472 $0.04 $0.04 $0.04
    22 Nov 2024 $0.04 $0.00 0.00% 11,493 $0.04 $0.04 $0.04
    21 Nov 2024 $0.03 $0.00 0.00% 617 $0.03 $0.03 $0.03
    20 Nov 2024 $0.04 $0.00 0.00% 312,990 $0.04 $0.04 $0.03
    19 Nov 2024 $0.04 $0.00 0.00% 362,647 $0.04 $0.04 $0.04
    18 Nov 2024 $0.04 $-0.01 -20.83% 363,031 $0.05 $0.05 $0.04
    15 Nov 2024 $0.05 $0.00 0.00% 164,412 $0.05 $0.05 $0.05
    14 Nov 2024 $0.05 $0.00 0.00% 453,924 $0.05 $0.05 $0.05
    13 Nov 2024 $0.05 $0.00 0.00% 6,250 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Aug 2024 Brett Mitchell Issued 1,250,000 $48,750
    Issue of securities. 1,250,000 Rights
    22 Aug 2024 Robert Proulx Issued 2,000,000 $78,000
    Issue of securities. 2,000,000 Unlisted Performance Rights, As per announcement on 23-08-2024
    27 Jun 2024 Brett Mitchell Buy 20,908 $1,744
    On-market trade.
    19 Jun 2024 Brett Mitchell Buy 88,569 $7,971
    On-market trade.
    18 Jun 2024 Brett Mitchell Buy 120,216 $10,537
    On-market trade.
    17 Jun 2024 Brett Mitchell Buy 91,551 $7,173
    On-market trade.
    14 Jun 2024 Brett Mitchell Buy 199,664 $14,816
    On-market trade.
    20 Dec 2023 Isaac Bright Issued 187,500 $64,687
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Melanie Jaye Leydin Company Secretary Non-Execufive Director May 2024
    Ms Leydin has 25 years experience in the accounting profession and over 15 years as a company secretary with experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementations of corporate governance, statutory financial reporting, re-organisation of Companies and shareholder relations.
    Mr Brett Anthony Mitchell Non-Executive Director Jun 2024
    Mr Mitchell is a corporate finance executive with more than 15 years of experience in ASX listed companies leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly-listed companies, including recently as a director of ASX listed lithium developer Delta Lithium Ltd (DLI), the dual ASX-LSE listed medical cannabis company Argent Biopharma Ltd (RGT), and is currently Executive Chairman of ASX listed Javelin Minerals Ltd (ASX:JAV) and Non-Executive Chairman of Uvre Limited (ASX :UVA).
    Mr Robert Romeo Proulx Executive DirectorExecutive Chairman Dec 2016
    Mr Proulx's previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management with more than 25 years' experience in the computer, life science and medical diagnostics industries. Some of Robert's other relevant experience include : Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.
    Geoff Hollis Chief Financial Officer / Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 1,211,054 3.71%
    HSBC Custody Nominees (Australia) Limited 713,860 2.19%
    Mr Haojie Li 610,438 1.87%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 542,204 1.66%
    Skicorp Pty Ltd <Gulabovski Sf A/C> 294,002 0.90%
    Mr Xucong Wu 268,032 0.82%
    The Board Of Regents Of The University Of Texas System 263,227 0.81%
    HSBC Custody Nominees (Australia) Limited A/C 2 253,633 0.78%
    Mr Anestis Lazaridis 243,595 0.75%
    E & W Nominee Pty Ltd <Liang Family Super Fund A/C> 240,238 0.74%
    Mr Kassem Bedran 239,556 0.73%
    Wh & Pr Pty Ltd <Robhoo Unit A/C> 225,000 0.69%
    Dr Reza Hayatbakhsh & Mrs Fahimeh Motamedi 200,000 0.61%
    Finclear Services Pty Ltd <Superhero Securities A/C> 197,150 0.60%
    Bnp Paribas Noms Pty Ltd 186,790 0.57%
    Mr Robert Proulx 154,082 0.47%
    Timarc Nominees Pty Ltd 150,000 0.46%
    Long Tall Kathy Pty Ltd <Long Tall Kathy Family A/C> 140,000 0.43%
    Miss Hengdi Zhang 135,794 0.42%
    Miss Christine Chen 135,000 0.41%

    Profile

    since

    Note